Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,144.6
5.8 (0.19%)

 

  • STI Straits Times Index
    3,144.6
    5.8 (0.19%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,514.6
    -
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,086.4
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,381.2
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,739.9
    -230.3 (-0.82%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,097.0
    -
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 0.7M
  • Value: 4.9M
  • Rise: -
  • Fall: -
  • Unch: 761

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Metal Component0.059+0.002
MM2 Asia0.073+0.006
Olam Intl1.280-0.060
KTL Global^0.124+0.002
CapAllianz0.004+0.001
HPH Trust USD0.225-
Shen Yao0.006-
CapLand IntCom T2.120+0.020
Serial System0.145+0.009
GSS Energy0.067-

World Indices

World Indices
Name Last Change
Nasdaq 14,660.6 -180.1
HSI 25,086.4
HSCEI 8,879.6
Jakarta 6,097.0
Nikkei 225 27,790.8 -179.5
SSE Comp 3,381.2
Shanghai A 3,543.7
Shanghai B 256.9
KOSPI 3,239.8 +7.3

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

RACE ONCOLOGY LTD RACE ONCOLOGY
Updated on 27 Jul 2021 (End of trading day)
Last (AUD): 3.610 Change: -0.020 High: 3.700 Remarks: -
Change (%): -0.55 Low: 3.610
Open 3.680 Yesterday's Close 3.63
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 128,609 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (AUD) a -0.02663 Trailing EPS (AUD) e -0.03050 NAV (AUD) b 0.0654
PE a - Trailing PE f - Price / NAV b 55.1988
Dividend (AUD) d - Cash In Hand (AUD) g 0.0386 Issued & Paid-up Shares c 144,401,000
Dividend Yield (%) d - Price / Cash In Hand g 93.523 Treasury Shares h -
Beta - 75 Daysi 0.985 R-Squared - 75 Days(%)i 0.67 Market Cap (M) 521.288
Beta - 500 Daysi 1.153 R-Squared - 500 Days (%)i 0.97 Enterprise Value (M) 515.711
Piotroski F Score 2 Exchange Code RAC Par Value ( AUD ) n.a.
52 Weeks Volatility (%) 79.18 Free Float (%) 52.4
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 07 Jul 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 14 Jul 2016.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference RACE ONCOLOGY LTD ASX 521.288 - - 55.1988 -
Industry Pharmaceuticals: Major ASX 135.719 - - 7.9945 -
Local Peer STARPHARMA HOLDINGS LIMITED ASX 552.266 - - 7.9162 -
Local Peer PYC THERAPEUTICS LIMITED ASX 477.139 - - 8.0214 -
Local Peer AFT PHARMACEUTICALS LTD ASX 453.260 63.921 63.919 13.4723 -
Local Peer NOXOPHARM LTD ASX 171.492 - - 5.7711 -
Local Peer RECCE PHARMACEUTICALS LTD ASX 178.991 - - 7.6694 -
Local Peer CRESO PHARMA LTD ASX 132.068 - - 9.6639 -
Local Peer EXOPHARM LTD ASX 76.193 - - 7.9508 -
Local Peer INVION LTD ASX 77.554 - - 14.0000 -
Local Peer MEDLAB CLINICAL LIMITED ASX 61.592 - - 7.5000 -
Local Peer PALLA PHARMA LTD ASX 59.908 - - 1.6584 -
Local Peer TBG DIAGNOSTICS LTD ASX 58.748 - - 10.1504 -
Local Peer PHARMAXIS ASX 42.121 - - 22.1429 -
Other Local Peers ONCOSIL MEDICAL LIMITED (ASX), TALI DIGITAL LIMITED (ASX), IMMURON LIMITED (ASX), ACRUX (ASX), ISLAND PHARMACEUTICALS LTD (ASX), SUDA PHARMACEUTICALS LTD (ASX), FIJI KAVA LTD (ASX), CELLMID LIMITED (ASX), FARMAFORCE LTD (ASX)
Global Peer JOHNSON & JOHNSON NYSE 452,602.458 30.760 25.474 - 2.315
Global Peer PFIZER INC NYSE 235,662.749 24.507 21.248 3.4343 3.614
Global Peer ELI LILLY AND COMPANY NYSE 233,599.553 37.716 38.342 33.8616 1.212
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 222,311.234 27.378 24.717 4.1137 2.111
Global Peer ABBVIE INC NYSE 208,043.054 45.664 40.921 15.1746 4.106
Global Peer MERCK & CO INC NYSE 195,576.314 27.675 27.828 7.2584 3.208
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 175,948.482 54.628 43.938 12.1932 2.044
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 158,236.431 24.556 23.538 17.1176 1.507
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 150,767.936 - - 4.0092 2.739
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 130,188.659 9.274 9.274 1.6889 2.596
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), HANSOH PHARMA (HKEx), VIATRIS INC (NASDAQ), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), REPLIGEN CORP (NASDAQ), CUREVAC NV (NASDAQ), SINOPHARM (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), ORGANON & CO (NYSE), HUTCHMED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), SH PHARMA (HKEx), JUNSHI BIO (HKEx), HYGEIA HEALTH (HKEx), REMEGEN-B (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), CMS (HKEx), AKESO-B (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), INNOCARE-B (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), BAIYUNSHAN PH (HKEx), ALLAKOS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), CHINARES PHARMA (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), KARUNA THERAPEUTICS INC (NASDAQ), SIMCERE PHARMA (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), TRAD CHI MED (HKEx), NEKTAR THERAPEUTICS (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), CHINAGRANDPHARM (HKEx), IGM BIOSCIENCES INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), OPKO HEALTH INC (NASDAQ), CSTONE PHARMA-B (HKEx), EVEREST MED-B (HKEx), HENLIUS (HKEx), ERASCA INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CARSGEN-B (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP (HKEx), HEPALINK (HKEx), OCUMENSION-B (HKEx), ADC THERAPEUTICS SA (NYSE), ZYMEWORKS INC (NYSE), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), Y-MABS THERAPEUTICS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), UNITED LAB (HKEx), ANTENGENE-B (HKEx), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), Kimia Farma Tbk. (IDX), REPARE THERAPEUTICS INC (NASDAQ), TONGRENTANGCM (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KRONOS BIO INC (NASDAQ), GENERATION BIO CO (NASDAQ), IMMUNOTECH-B (HKEx), FORMA THERAPEUTICS HLDGS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), PETIQ INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), SCICLONE PHARMA (HKEx), CKLIFE SCIENCES (HKEx), PHIBRO ANIMAL HEALTH CORP (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), ANNOVIS BIO INC (NYSE American), KEROS THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), GH RESEARCH PLC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), SHINEWAY PHARM (HKEx), ANNEXON INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), ZHAOKE OPHTH-B (HKEx), EVOLUS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), AC IMMUNE SA (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), HUA MEDICINE-B (HKEx), TARSUS PHARMACEUTICALS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), CLENE INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), Soho Global Health Tbk. (IDX), SIGA TECHNOLOGIES INC (NASDAQ), PHARVARIS NV (NASDAQ), INOZYME PHARMA INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), IGBB (Bursa), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), PROVENTION BIO INC (NASDAQ), BEYONDSPRING INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), XOMA CORP (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), BIOMEA FUSION INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), ATHENEX INC (NASDAQ), 89BIO INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), DAWNRAYS PHARMA (HKEx), THERATECHNOLOGIES INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), DURECT CORP (NASDAQ), BSTEAD (Bursa), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), GAMIDA CELL LTD (NASDAQ), TOT BIOPHARM-B (HKEx), VERRICA PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), VINCERX PHARMA INC (NASDAQ), PHARMA (Bursa), 180 LIFE SCIENCES CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), NEXIMMUNE INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), FUSEN PHARM (HKEx), IMMUNIC INC (NASDAQ), MUSTANG BIO INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), HARROW HEALTH INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), OBSEVA SA (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), IP (SET), LANNETT CO INC (NYSE), ONCTERNAL THERAPEUTICS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), CH BIOTECH SER (HKEx), PHASEBIO PHARMACEUTICALS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), LANTERN PHARMA INC (NASDAQ), IMARA INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), POLYPID LTD (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), ZHONGZHIPHARM (HKEx), IX Biopharma (SGX), AQUESTIVE THERAPEUTICS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), NOVAN INC (NASDAQ), ENTERA BIO LTD (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), EYENOVIA INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), GALECTO INC (NASDAQ), PROPHASE LABS INC (NASDAQ), MEDIWOUND LTD (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), NEW RAY MEDIC (HKEx), MOLECULIN BIOTECH INC (NASDAQ), CHARMACY PHAR (HKEx), GRAYBUG VISION INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), KOTRA (Bursa), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), Phapros Tbk. (IDX), DARE BIOSCIENCE INC (NASDAQ), PAK FAH YEOW (HKEx), NC HEALTHCARE (HKEx), Hyphens Pharma (SGX), EDESA BIOTECH INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), BIOHLDG (Bursa), NOVA (Bursa), MODERN CHI MED (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), MANNATECH INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), NEP INTERLONG (HKEx), ASSERTIO HOLDINGS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), ACURX PHARMACEUTICALS INC (NASDAQ), WAI YUEN TONG (HKEx), VIRIOS THERAPEUTICS INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), PURAPHARM (HKEx), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), SANAI HEALTH GP (HKEx), PANBELA THERAPEUTICS INC (NASDAQ), PAINREFORM LTD (NASDAQ), NLS PHARMACEUTICS LTD (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), JCT (SET), VALLON PHARMACEUTICALS INC (NASDAQ), SUNZEN (Bursa), AVENUE THERAPEUTICS INC (NASDAQ), EXTRAWELL PHAR (HKEx), PETROS PHARMACEUTICALS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), SINOLIFE UTD (HKEx), PASHUN INT'L (HKEx), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.020
+0.56 %
10 Days -+0.040
+1.12 %
20 Days --0.050
-1.37 %
Medium Term Return 3 Months -+0.500
+16.08 %
6 Months -+1.680
+87.05 %
1 Year -+2.725
+307.91 %
Long Term Return 2 Years -+3.548
+5722.58 %
3 Years -+3.420
+1800.00 %
5 Years -+3.355
+1315.69 %
Annualised Return Annualised --
+69.90 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.705 - 4.230 Change From 1 Year Low +2.905 % Change From 1 Year Low (%) +412.06
Change From 1 Year High -0.620 % Change From 1 Year High (%) -14.66
2 Years Range 0.060 - 4.230 Change From 2 Years Low +3.550 % Change From 2 Years Low (%) +5916.67
Change From 2 Years High -0.620 % Change From 2 Years High (%) -14.66
5 Years Range 0.045 - 4.230 Change From 5 Years Low +3.565 % Change From 5 Years Low (%) +7922.22
Change From 5 Years High -0.620 % Change From 5 Years High (%) -14.66
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Race Oncology Ltd. is a precision oncology company, with the phase 2/3 cancer drug, Bisantrene, which is a potent small molecule inhibitor of the Fatso (FTO) protein. It uses the Bisantrene in melanoma and clear cell renal cell, kidney, carcinoma, both frequent FTO-driven cancers. The firm also has compelling clinical data for the use of Bisantrene in Acute Myeloid Leukaemia, Breast, and Ovarian Cancer. The company was founded on February 15, 2011 and is headquartered in Sydney, Australia.

Historical Price Data

Date Open High Low Close Volume VWAP
27 Jul 2021 3.680 3.700 3.610 3.610 128,609 -
26 Jul 2021 3.690 3.750 3.630 3.630 185,850 -
23 Jul 2021 3.740 3.740 3.610 3.670 205,794 -
22 Jul 2021 3.750 3.840 3.690 3.700 285,757 -
21 Jul 2021 3.590 3.800 3.570 3.720 435,174 -
20 Jul 2021 3.560 3.590 3.530 3.590 104,545 -
19 Jul 2021 3.550 3.610 3.500 3.510 284,660 -
16 Jul 2021 3.520 3.560 3.490 3.530 119,626 -
15 Jul 2021 3.550 3.570 3.490 3.540 143,324 -
14 Jul 2021 3.510 3.570 3.480 3.530 189,634 -
13 Jul 2021 3.550 3.590 3.490 3.570 185,668 -
12 Jul 2021 3.500 3.620 3.500 3.510 140,131 -
09 Jul 2021 3.570 3.570 3.500 3.510 207,780 -
08 Jul 2021 3.580 3.690 3.570 3.580 174,474 -
07 Jul 2021 3.590 3.620 3.560 3.570 216,092 -
06 Jul 2021 3.610 3.650 3.590 3.600 160,659 -
05 Jul 2021 3.650 3.690 3.590 3.600 255,161 -
02 Jul 2021 3.700 3.700 3.620 3.630 120,386 -
01 Jul 2021 3.650 3.780 3.620 3.690 246,486 -
30 Jun 2021 3.730 3.730 3.640 3.670 162,086 -
29 Jun 2021 3.650 3.740 3.640 3.660 220,376 -
28 Jun 2021 3.700 3.730 3.550 3.620 264,850 -
Summary
Current 2 Weeks
(14 Jul 2021 to 27 Jul 2021)
3.510 3.840 3.480 3.610 2,082,973 -
Previous 2 Weeks
(30 Jun 2021 to 13 Jul 2021)
3.730 3.840 3.480 3.570 1,868,923 -
4 Weeks from
(01 Jun 2021 to 29 Jun 2021)
3.440 3.840 3.390 3.660 8,466,133 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.